Comano's (Trentino) thermal water interferes with the expression and secretion of vascular endothelial growth factor-A protein isoforms by cultured human psoriatic keratinocytes: A potential mechanism of its anti-psoriatic action

International Journal of Molecular Medicine

Volumn 18, Issue 1, 2006, Pages 17-25

  Chiarini, Anna ^a   Dal Pra, Ilaria ^a   Pacchiana, Raffaella ^a   Menapace, Lia ^a   Zumiani, Giuseppe ^b   Zanoni, Mauro ^c   Armato, Ubaldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c Research Centre   (Italy)

Author keywords

Chemokines; Comano's thermal water; Cytokines; Human keratinocytes; Psoriasis; Vascular endothelial growth factor A

Indexed keywords

HYPOTONIC SOLUTION; ISOPROTEIN; MINERAL WATER; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; HUMAN; ITALY; KERATINOCYTE; METABOLISM; PATHOLOGY; PSORIASIS; SECRETION; SKIN; TIME;

CELLS, CULTURED; HUMANS; HYPOTONIC SOLUTIONS; ITALY; KERATINOCYTES; MINERAL WATERS; PROTEIN ISOFORMS; PSORIASIS; SKIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748210877     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.1.17     Document Type: Article

References (74)

1. Bos JD and De Rie MA: The pathogenesis of psoriasis. Immunol Today 20: 40-46, 1999.
2. Telner P and Fekete Z: The capillary responses in psoriatic skin. J Invest Dermatol 36: 225-230, 1961.
3. Creamer D, Allen MH, Sousa A, Poston R and Barker JN: Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136: 859-865, 1997.
4. Braverman IM and Sibley J: Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 78: 12-17, 1982.
5. Schubert C and Christophers E: Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 277: 352-358, 1985.
6. Folkman J: Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 59: 40-43, 1972.
7. Barker JN: The pathophysiology of psoriasis. Lancet 338: 227-230, 1991.
8. Goodfield M, Hull SM, Holland D, Roberts G, Wood E, Reid S and Cunliffe W: Investigations of the 'active' edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin. Br J Dermatol 131: 808-813, 1994.
9. Creamer D, Sullivan D, Bicknell R and Barker J: Angiogenesis in psoriasis. Angiogenesis 5: 231-236, 2002.
10. Malhotra R, Stenn KS, Fernandez LA and Braverman IM: Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. Lab Invest 61: 162-165, 1989.
11. Barnhill RL, Parkinson EK and Ryan TJ: Supernatants from cultured human epidermal keratinocytes stimulate angiogenesis. Br J Dermatol 110: 273-281, 1984.
12. Nickoloff BJ, Mitra RS, Varani J, Dixit VM and Polverini PJ: Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144: 820-828, 1994.
13. Ettehadi P, Greaves MW, Wallach D, Aderka D and Camp RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146-151, 1994.
14. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ Jr, Ellingsworth L, Derynck R and Voorhees JJ: Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243: 811-814, 1989.
15. Creamer D, Jaggar R, Allen M, Bicknell R and Barker J: Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137: 851-855, 1997.
16. Bonifati C and Ameglio F: Cytokines in psoriasis. Int J Dermatol 38: 241-251, 1999.
17. Blumberg H, Conklin D, Xu WF, et al: Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104: 9-19, 2001.
18. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B and Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141-1146, 1994.
19. Bhushan M, McLaughlin B, Weiss JB and Griffiths CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141: 1054-1060, 1999.
20. Gimbrone MA Jr, Obin MS, Brock AF, et al: Endothelial interleukin- 8: a novel inhibitor of leukocyte-endothelial interactions. Science 246: 1601-1603, 1989.
21. Thomas KA: Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271: 603-606, 1996.
22. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
23. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989. (Pubitemid 20066717)
24. Vincenti V, Cassano C, Rocchi M and Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93: 1493-1495, 1996.
25. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
26. Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814, 1991.
27. Whittle C, Gillespie K, Harrison R, Mathieson PW and Harper SJ: Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci 97: 303-312, 1999.
28. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E and Neufeld G: VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151-7158, 1997.
29. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R and Ferrara N: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271: 7788-7795, 1996.
30. Lei J, Jiang A and Pei D: Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1443: 400-406, 1998.
31. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
32. Kroupis C, Stathopoulou A, Zygalaki E, Ferekidou L, Talieri M and Lianidou ES: Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem 38: 50-57, 2005.
33. Ballaun C, Weninger W, Uthman A, Weich H and Tschachler E: Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 104: 7-10, 1995.
34. Wellmann S, Taube T, Paal K, Graf V, Einsiedel H, Geilen W, Seifert G, Eckert C, Henze G and Seeger K: Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin Chem 47: 654-660, 2001.
35. Huez I, Bornes S, Bresson D, Creancier L and Prats H: New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15: 2197-2210, 2001.
36. Tee KM and Jaffe BJ: A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon. Biochem J 359: 219-226, 2001.
37. Bornes S, Boulard M, Hieblot C, Zanibellato C, Iacovoni JS, Prats H and Touriol C: Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternative spliced coding sequences. J Biol Chem 279: 18717-18726, 2004.
38. Potgens AJ, Lubsen NH, van Altena MC, Vermeulen R, Bakker A, Schoenmakers JG, Ruiter DJ and De Waal RM: Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem 9: 32879-32885, 1994.
39. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H and Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519-524, 1990.
40. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D and Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586, 1992.
41. Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R and Alitalo K: FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 52: 5738-5743, 1992.
42. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H and Ferrara N: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271: 5638-5646, 1996.
43. Soker S, Takashima S, Miao HQ, Neufeld G and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998. (Pubitemid 28155313)
44. Alon T, Hemo I, Itin A, Pe'er J, Stone J and Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028, 1995.
45. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ and Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996.
46. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
47. Fong GH, Rossant J, Gertsenstein M and Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995.
48. Volm M, Koomagi R and Mattern J: Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res 16: 213-217, 1996. (Pubitemid 26128469)
49. Detmar M, Yeo KT, Nagy JA, van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S and Dvorak HF: Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105: 44-50, 1995.
50. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP and Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111: 1-6, 1998. (Pubitemid 28309201)
51. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD and Rudge JS: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102: 161-168, 2003. (Pubitemid 36759650)
52. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS and Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276: 7614-7620, 2001. (Pubitemid 37392076)
53. Lee TH, Avraham H, Lee SH and Avraham S: Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 277: 10445-10451, 2002. (Pubitemid 34968165)
54. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A and Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343, 1996. (Pubitemid 26115364)
55. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J and Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271: 17629-17634, 1996. (Pubitemid 26250731)
56. Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T and Hiragun A: Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 178: 247-250, 1990.
57. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M and Michel S: Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 275: 642-650, 2000.
58. Hernandez GL, Volpert OV, Iniguez MA, Lorenzo E, Martinez- Martinez S, Grau R, Fresno M and Redondo JM: Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 193: 607-620, 2001.
59. Zumiani G, Zanoni M and Agostini G: Valutazione dell'efficacia dell'acqua della fonte termale di Comano versus acqua di acquedotto nella cura della psoriasi. G Ital Dermatol Venereol 135: 1-5, 2000.
60. Grice KA: Transepidermal water loss in pathological skin. In: Physiology and Pathophysiology of the Skin. Jarret A (ed). Academic Press, London, pp2147-2155, 1980.
61. Harding CR: The stratum corneum: structure and function in health and disease. Dermatol Ther 17 (Suppl 1): S6-S15, 2004.
62. Tsoureli-Nikita E, Menchini G, Ghersetich I and Hercogova J: Alternative treatment of psoriasis with balneotherapy using Leopoldine spa water. J Eur Acad Dermatol Venereol 16: 260-262, 2002.
63. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
64. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K and Hamakawa H: Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 40: 13-20, 2004. (Pubitemid 37510207)
65. Houck KA, Leung DW, Rowland AM, Winer J and Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanism. J Biol Chem 267: 26031-26037, 1992.
66. Yeo TK, Senger DR, Dvorak HF, Freter L and Yeo KT: Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). Biochem Biophys Res Commun 179: 1568-1575, 1991.
67. Zhang Y, Matsuo H and Morita E: Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales. Exp Dermatol 14: 758-764, 2005.
68. Muller YA, Christinger HW, Keyt BA and De Vos AM: The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 5: 1325-1338, 1997.
69. Park JE, Keller GA and Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326, 1993.
70. Cheng SY, Nagane M, Huang HS and Cavenee WK: Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 94: 12081-12087, 1997.
71. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S and Bayard F: Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272: 13390-13396, 1997.
72. Ancelin M, Buteau-Lozano H, Meduti G, Osborne-Pellegrin M, Sordello S, Plouet J and Perrot-Applanat M: A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci USA 99: 6023-6028, 2002. (Pubitemid 34493258)
73. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ and Neufeld G: VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270: 11322-11326, 1995.
74. Clauss MJ, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YCE, Olander JV, Connoly DT and Stern D: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration J Exp Med 172: 1535-1545, 1990.